Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time
Senseonics Holdings, a pioneer in medical technology focusing on implantable continuous glucose monitoring (CGM) systems for diabetes patients, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss Q1 2025 performance. Investors can participate through multiple channels:
- Conference call: US/Canada: 1-800-343-4136
- International: 1-203-518-9843
- Passcode: SENSQ1
- Webcast: Available on www.senseonics.com under Investor Relations
The webcast will be archived on the company's website for future reference. Participants are advised to dial in 5-10 minutes before the start time.
Senseonics Holdings, azienda pioniera nella tecnologia medica specializzata in sistemi impiantabili di monitoraggio continuo del glucosio (CGM) per pazienti diabetici, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per l'8 maggio 2025, dopo la chiusura dei mercati.
L'azienda terrà una conference call alle 16:30 ora della costa orientale dello stesso giorno per discutere le performance del primo trimestre 2025. Gli investitori potranno partecipare tramite diversi canali:
- Conference call: USA/Canada: 1-800-343-4136
- Internazionale: 1-203-518-9843
- Codice di accesso: SENSQ1
- Webcast: disponibile su www.senseonics.com nella sezione Relazioni con gli Investitori
La registrazione del webcast sarà archiviata sul sito web dell'azienda per consultazioni future. Si consiglia ai partecipanti di collegarsi 5-10 minuti prima dell'inizio della chiamata.
Senseonics Holdings, pionera en tecnología médica enfocada en sistemas implantables de monitoreo continuo de glucosa (CGM) para pacientes con diabetes, ha programado el anuncio de resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025, después del cierre del mercado.
La compañía realizará una conferencia telefónica a las 4:30 PM hora del Este el mismo día para discutir el desempeño del primer trimestre de 2025. Los inversores pueden participar a través de varios canales:
- Conferencia telefónica: EE. UU./Canadá: 1-800-343-4136
- Internacional: 1-203-518-9843
- Código de acceso: SENSQ1
- Transmisión en vivo: disponible en www.senseonics.com en la sección Relaciones con Inversionistas
La transmisión en vivo quedará archivada en el sitio web de la compañía para futuras consultas. Se recomienda a los participantes marcar entre 5 y 10 minutos antes del inicio.
Senseonics Holdings는 당뇨병 환자를 위한 이식형 연속 혈당 모니터링(CGM) 시스템에 중점을 둔 의료 기술 분야의 선구자로, 2025년 1분기 재무 결과 발표를 2025년 5월 8일 장 마감 후로 예정하고 있습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 2025년 1분기 실적에 대해 논의하는 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 여러 채널을 통해 참여할 수 있습니다:
- 컨퍼런스 콜: 미국/캐나다: 1-800-343-4136
- 국제: 1-203-518-9843
- 접속 코드: SENSQ1
- 웹캐스트: www.senseonics.com 투자자 관계 섹션에서 이용 가능
웹캐스트는 회사 웹사이트에 아카이브되어 추후 참고할 수 있습니다. 참가자들은 시작 5-10분 전에 접속할 것을 권장합니다.
Senseonics Holdings, pionnière dans la technologie médicale spécialisée dans les systèmes implantables de surveillance continue du glucose (CGM) pour les patients diabétiques, a programmé l'annonce des résultats financiers du premier trimestre 2025 pour le 8 mai 2025, après la clôture du marché.
L'entreprise tiendra une conférence téléphonique à 16h30 heure de l'Est le même jour pour discuter des performances du premier trimestre 2025. Les investisseurs peuvent participer via plusieurs moyens :
- Conférence téléphonique : États-Unis/Canada : 1-800-343-4136
- International : 1-203-518-9843
- Code d'accès : SENSQ1
- Webdiffusion : disponible sur www.senseonics.com dans la section Relations Investisseurs
La webdiffusion sera archivée sur le site de l'entreprise pour consultation ultérieure. Il est conseillé aux participants de se connecter 5 à 10 minutes avant le début.
Senseonics Holdings, ein Vorreiter in der Medizintechnik mit Schwerpunkt auf implantierbaren Systemen zur kontinuierlichen Glukoseüberwachung (CGM) für Diabetespatienten, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse des ersten Quartals 2025 zu besprechen. Investoren können über verschiedene Kanäle teilnehmen:
- Telefonkonferenz: USA/Kanada: 1-800-343-4136
- International: 1-203-518-9843
- Zugangscode: SENSQ1
- Webcast: Verfügbar auf www.senseonics.com unter Investor Relations
Der Webcast wird auf der Unternehmenswebsite archiviert und steht für spätere Abrufe zur Verfügung. Teilnehmer werden gebeten, sich 5-10 Minuten vor Beginn einzuwählen.
- None.
- None.
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 8, 2025.
Management will hold a conference call to review the Company’s first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-343-4136 (US/Canada) or 1-203-518-9843 (International), passcode SENSQ1, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
When will Senseonics (SENS) release Q1 2025 earnings?
How can I listen to Senseonics (SENS) Q1 2025 earnings call?
What time is Senseonics (SENS) Q1 2025 earnings conference call?
Where can I find Senseonics (SENS) Q1 2025 earnings webcast?
What does Senseonics (SENS) company do?
